Result of General Meeting

TURKU - FINLAND 2 March 2026 – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the Company took place today, 2 March 2026 in Turku, Finland. The EGM approved the proposal of the Board of Directors ("Board") as set out in the notice to the EGM published on 9 February 2026.

Decisions of the EGM

Authorising the Board to resolve on the rights offering

The Board was authorized by the EGM to resolve on the issuance of a maximum of 80,000,000 new shares in a rights offering as follows:

The new shares to be issued based on the authorisation will be offered to the Company's shareholders for subscription pursuant to their pre-emptive subscription rights in the same proportion as they already hold shares in the Company. Shares that remain unsubscribed at the end of the subscription period of the rights offering on the basis of shareholders' pre-emptive subscription rights may be offered on a secondary basis for subscription to other shareholders or third parties. The Board is authorised to decide to whom such shares that remain unsubscribed, if any, are offered to. In the event that shares are to be issued to potential subscription guarantors in a secondary offering, the Company is authorised to issue the shares to itself first without consideration to enable delivery versus payment in respect of such subscription guarantors (without the authorisation being exercised twice in respect of such shares). The Board is authorised to resolve on all other terms and conditions of the rights offering, including the subscription and payment period and the grounds for determining the subscription price.

The authorisation is valid until 30 June 2026 and does not revoke the authorisation granted to the Board by the Annual General Meeting on 21 March 2025 to resolve on issuances of shares, option rights or other special rights entitling to shares.

Minutes of the EGM

The minutes of the EGM will be available on the Company’s website on 16 March 2026 at the latest.

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments by targeting Clever-1, a receptor on immunosuppressive macrophages and malignant blasts. By inhibiting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment.

About Faron Pharmaceuticals Ltd.

Faron Pharmaceuticals (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The Company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.